Compare BLDR & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | QGEN |
|---|---|---|
| Founded | 1998 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 10.2B |
| IPO Year | 2005 | 1998 |
| Metric | BLDR | QGEN |
|---|---|---|
| Price | $82.04 | $40.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $132.29 | $51.30 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.88% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | $1.00 | $8.18 |
| Revenue Next Year | $4.52 | $5.71 |
| P/E Ratio | ★ $20.34 | $24.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $76.50 | $38.58 |
| 52 Week High | $151.03 | $57.82 |
| Indicator | BLDR | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 40.25 |
| Support Level | $80.00 | $38.80 |
| Resistance Level | $130.47 | $48.60 |
| Average True Range (ATR) | 3.65 | 0.86 |
| MACD | 0.59 | 0.38 |
| Stochastic Oscillator | 36.64 | 71.25 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).